Although radioiodine theraphy (RAIT) is thought to affect blood cells and oxidative stress, hemorheological alterations following dose-dependent RAIT remains unknown.
OBJECTIVE:
The aim of this study was to determine the effects of RAIT on hemorheological and oxidative stress parameters in patients with differentiated thyroid cancers (DTC).
METHODS:
Totally 31 DTC patients (mean age 46.32±11.15 years) and 26 healthy controls (mean age 50.50±6.22 years) were included. Venous blood samples were collected from each patient before and after treatment (7th day, 1th month and 6th month). Erythrocyte aggregation-deformability and oxidative stress parameters were determined. p < 0.05 was considered as statistically significant.
RESULTS:
Erythrocyte deformability of the patients determined at 16.87 and 30 Pascal were significantly lower than healthy individuals. Erythrocyte aggregation index (AI) of the patients was higher, whereas erythrocyte aggregation half-time (t½) was lower compared to control. Erythrocyte deformability values and AI were not significantly different from the pre- and post-radioiodine treatment groups. There was no statistically significant difference between the oxidative stress parameters before and after the treatment.
CONCLUSIONS:
Patients were in a worse hemorheological condition compared to healthy individuals. After RAIT, RBC deformability and aggregation were not affected and no significant change in oxidative stress parameters was detected.
DeGrootLJ, KaplanEL, McCormickM. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab1990;71[2]:414-24.
3.
SengozT, SürücüE, DemirY, DerebekE. The effects of the factors related to the patient and the disease on the performance of ablation therapy in patients with differentiated thyroid cancer who have received I-131 ablation therapy. Mol Imaging Radionucl Ther. 2012;21:103–9.
MingzhaoX. Oxidative stress: a new risk factor for thyroid cancer. Endocr Relat Cancer. 2012;19:7–11.
6.
DrögeW. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47–95.
7.
ValkoM, LeibfritzD, MoncolJ, CroninMTD, MazurM, TelserJ. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39:44–84.
8.
van BeersEJ, van WijkR. Oxidative stress in sickle cell disease; more than a DAMP squib. Clin Hemorheol Microcirc. 2018;68:239–50.
9.
NuceraC, LawlerJ, ParangiS. BRAF V600E and microenvironment in thyroid cancer: functional link to drive cancer progression. Cancer Res. 2011;71:2417–422.
10.
SadaniGR, NadkarniGD. Role of tissue antioxidant defence in thyroid cancers. Cancer Lett. 1996;109:231–35.
11.
ErdamarH, CimenB, GulcemalH, SaraymenR, YererB, DemirciH. Increased lipid peroxidation and impaired enzymatic antioxidant defense mechanism in thyroid tissue with multinodular goiter and papillary carcinoma. Clin Biochem. 2010;43:650–54.
12.
AkinciM, KosovaF, CetinB, SepiciA, AltanN, AslanS, et al. Oxidant/antioxidant balance in patients with thyroid cancer. Acta Cir Bras. 2008;23:551–54.
13.
WangD, FengJ, ZengP, YangY, LuoJ, YangY. Total oxidant/antioxidant status in sera of patients with thyroid cancers. Endocrine-Related Cancer. 2011;18:773–82.
14.
YoungO, CrottyT, O’ConnellR, O’SullivanJ, CurranAJ. Levels of oxidative damage and lipid peroxidation in thyroid neoplasia. Head Neck. 20096;32:750–56.
15.
WangHQ, GuanY, DuZX, ZhangHY, MengX. Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer. 2009;9:1–11.
16.
HalliwellB, GutteridgeJMJ. The importance of free radicals and catalytic metal ions in human diseases. Mol Aspects Med. 1985;8:89–193.
17.
VrndicOB, RadivojevicSD, JovanovicMD, DjukicSM, TeodorovicLCM, SimonovicSTZ. Oxidative stress in patients with differentiated thyroid cancer: early effects of radioiodine therapy. Indian J Biochem Biophys. 2014;51:223–29.
18.
Ish-ShalomS, DurleshterL, SegalE, NaglerRM. Sialochemical and oxidative analyses in radioactive I131-treated patients with thyroid carcinoma. Eur J Endocrinol. 2008;158:677–81.
19.
WolframRM, BudinskyAC, PalumboB, PalumboR, SinzingerH. Radioiodine therapy induces dose-dependent in vivo oxidation injury: evidence by increased isoprostane 8-Epi-PGF2α. J Nucl Med. 2002;43:1254–258.
20.
ArikanS, DemirM, AkcayT, KonukogluD, HatemiHH. Radioiodine treatment and oxidative stress in thyroidectomised patients for differentiated thyroid cancers. Pharmacol Res. 2002;38:311–15.
21.
KonukogluD, HatemiHH, ArikanS, DemirM, AkcayT. Radioiodine treatment and oxidative stress in thyroidectomised patients for differentiated thyroid cancers. Pharmacol Res. 1998;38:311–15.
22.
MakarewiczJ, LewiskiA, Karbownik-LewiskaM. Radioiodine remnant ablation of differentiated thyroid cancer does not further increase oxidative damage to membrane lipids - early effect. Thyroid Res. 2010;3:2–5.
23.
MohandasN, ChasisJA, ShohetSB. The influence of membrane skeleton on red cell deformability, membrane material properties, and shape. Semin Hematol. 1983;20:225–42.
24.
StuartJ, NashGB. Red cell deformability and haematological disorders. Blood Rev. 1990;4:141–47.
25.
Kilic-ToprakE, YaylaliO, YaylaliYT, OzdemirY, YukselD, SenolH, et al. Hemorheological dysfunction in cardiac syndrome X. Acta Cardiol. 2018;73:257–65.
26.
StraatM, Van BruggenR, de KorteR, JuffermansNP. Red blood cell clearance in inflammation. Transfus Med Hemother. 2012;39:353–61.
27.
HalliwellB, GutteridgeJMJ. Free Radicals in Biology and Medicine. Oxford University Press, 2015.
28.
BaskurtOK, BoynardM, CokaletGC, ConnesP, CookeBM, ForconiS, et al. New guidelines for hemorheological laboratory techniques. Clin Hemorheol Microcirc. 2009;42:75–97.
29.
HolmS, JonasM. Engaging the World: The Use of Empirical Research inBioethics and the Regulation of Biotechnology. In: Handbook of Hemorheology and hemodynamics,
BaskurtOK,
HardemanMR,
RamplingMW,
MeiselmanHJ [eds.], IOS Press: 2007.
30.
ErelO. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;37:277–85.
31.
ErelO. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38:1103–111.
DasKC, MukherjeeM, SarkarTK, DashRJ, RastogiGK. Erythropoiesis and erythropoietin in hypo- and hyperthyroidism. J Clin Endocrinol Metab. 1975;40:211–20.
34.
DorgalalehA, MahmoodiM, VarmaghaniB, Kiani NodeF, Saeeidi KiaO, AlizadehSh, et al. Effect of thyroid dysfunctions on blood cell count and red blood cell indice. Iran J Pediatr Hematol Oncol. 2013;3:73–7.
35.
RileyPA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol. 1994;65:27–33.
36.
DemirY, UclerR, SurucuE, TuranM, BalliZ, SengozT. Temporary changes in neutrophil-to-lymphocyte, platelet-to-lymphocyte ratios, and mean platelet volume reflecting the inflammatory process after radioiodine therapy. Nucl Med Commun. 2016;37:393–98.
37.
MolinaroE, LeboeufR, ShueB, MartorellaAJ, FleisherM, LarsonS, et al. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. Thyroid. 2009;19:1035–41.
38.
HaynieTP, BeierwaltesWH. Hematologic changes observed following I-131 therapy for thyroid carcinoma. J Nucl Med. 1963;4:85–91.
39.
BenuaRS, CicaleNR, SonenbergM, RawsonRW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171–82.
40.
HuT, MengZ, ZhangG, JiaQ, TanJ, ZhengW, et al. Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer. Med. 2016;95:no pagination.
MuravyovAV, DrayginSV, EreminNN, MuravyovAA. The microrheological behaviour of young and old red blood cells in athletes. Clin Hemorheol Microcirc. 2002;26:183–88.
43.
JungF, MrowietzC, HieblB, FrankeRP, PindurG, SternitzkyR. Influence of rheological parameters on the velocity of erythrocytes passing nailfold capillaries in humans. Clin Hemorheol Microcirc. 2011;48:129–39.
44.
Von TempelhoffGF, HeilmannL, HommelG, PollowK. Impact of rheological variables in cancer. Semin Thromb Hemost. 2003;29:499–513.
45.
RicklesFR, EdwardsRL, BarbC, CronlundM. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer. 1983;51:301–7.
46.
von TempelhoffGF, NiemannF, SchneiderDM, KirkpatrickCJ, HommelG, HeilmannL. Blood rheology during chemotheraphy in patients with ovarian cancer. Thromb Res. 1998;90:73–82.
47.
MillerB, HeilmannL. Hemorheological parameters in patients with gynecologic malignancies. Gynecol Oncol. 1989;33:177–81.
48.
RoitmanEV, KolesnikovaIM, DavydkinIL, KozlakaNS, RoumiantsevSA. Hemorheologic disturbances as thrombosis risk factor in patients with some myeloproliferative neoplasms. Thromb Res. 2016;140(Supp 1), 198.
49.
BalciYI, AgladiogluS, AgladiogluK, ToprakEK, ErkekOK, OzhanB, et al. Impaired hemorheological parameters and increased carotid intima-media thickness in children with subclinical hypothyroidism. Horm Res Paediatr. 2016;85:250–56.
50.
KöltringerP, EberO, WakonigP, KlimaG, LindP. Hypothyroidism and the influence on human blood rheology. J Endocrinol Invest. 1988;11:267–72.
51.
YedgarS, KoshkaryevA, BarshteinG. The red blood cell in vascular occlusion. Pathophysiol Haemost Thromb. 2002;32:263–68.
52.
KimYK, KwonEH, KimDH, WonD, ShinS, SuhJS. Susceptibility of oxidative stress on red blood cells exposed to gamma rays: hemorheological evaluation. Clin Hemorheol Microcirc. 2008;40:315–24.
53.
AnandAJ, DzikWH, ImamA, SadrzadehSMH. Radiation-induced red cell damage: role of reactive oxygen species. Transfusion. 1997;37:160–65.
